鼻咽癌腮腺淋巴结转移患者调强放疗时代的临床治疗考虑
本研究基于大样本平台鼻咽癌数据库,回顾2008至2019年在本中心接受调强放疗的10685例初诊非远处转移鼻咽癌患者,其中275例(2.5%)存在腮腺淋巴结转移。研究发现腮腺淋巴结根治性调强放疗组生存优于腮腺保留组,在190例接受根治性调强放疗的患者中,VIII区D95%>55 Gy是全生存的独立有益预后因素。作者据此推荐将同侧VIII区纳入低危临床靶区(CTV2)。
要点
- 275/10685例(2.5%)鼻咽癌患者存在腮腺淋巴结转移,367个阳性淋巴结中199个位于腮腺内浅叶。
- 腮腺淋巴结根治性调强放疗组生存结局优于腮腺保留组。
- 在190例接受根治性调强放疗患者中,VIII区D95%>55 Gy为全生存的独立有益预后因素。
核心结论
- 基于鼻咽癌腮腺淋巴结转移的分布模式和剂量探索研究结果,推荐将同侧VIII区纳入低危临床靶区(CTV2)。
研究设计与样本
- 回顾性分析大数据平台鼻咽癌数据库,纳入2008至2019年在本中心接受调强放疗的10685例初诊、非远处转移、组织学确诊的鼻咽癌患者,其中存在腮腺淋巴结转移者纳入本研究。
- 从剂量体积直方图(DVH)收集剂量学参数,主要终点为全生存(OS),采用最小绝对收缩和选择算子回归(LASSO)进行变量筛选,多因素Cox回归分析确定独立预后因素。
主要发现
- 275/10685例(2.5%)患者存在腮腺淋巴结转移,367个阳性腮腺淋巴结中199个位于腮腺内浅叶,70个位于腮腺内深叶,54个位于腮腺下,44个位于耳前皮下。
- 与腮腺保留组相比,腮腺淋巴结根治性调强放疗组观察到更好的生存结局。
- 在190例接受腮腺淋巴结根治性调强放疗的患者中,多因素分析显示VIII区D95%>55 Gy是全生存(OS)、无进展生存(PFS)、无远处转移生存(DMFS)和腮腺无复发生存(PRFS)的独立有益预后因素。
临床怎么用
- 作者基于分布模式和剂量探索结果推荐,对存在腮腺淋巴结转移的鼻咽癌患者,将同侧VIII区纳入低危临床靶区(CTV2)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No specific irradiation guidelines have been proposed for parotid lymph node (PLN) metastasis in patients with nasopharyngeal carcinoma (NPC). This study aimed to explore the dose prescription and target delineation for PLN metastasis in patients with NPC. METHODS: With the NPC database from a big-data platform, 10,685 patients with primarily diagnosed, non-distant metastatic, histologically proven NPC and treated with intensity modulated radiotherapy (IMRT) at our center from 2008 to 2019 were reviewed and those with PLN metastasis were enrolled in this study. Dosimetry parameters were collected from the dose-volume histograms (DVH). The primary endpoint was overall survival (OS). Least absolute shrinkage and selection operator regression (LASSO) was operated for variable selection. Multivariate Cox regression analysis was applied to identify the independent prognostic factors. RESULTS: PLN metastases were identified in 275/10685 (2.5%) patients. Of 367 positive PLN, 199 were in superficial intra-parotid, followed by 70 in deep intra-parotid, 54 in subparotid and 44 in subcutaneous pre-auricular. Better survival outcome was observed in PLN-radical IMRT group, compared with PLN-sparing group. In 190 patients received PLN-radical IMRT, multivariate analysis revealed that D95% of level VIII > 55 Gy was an independent beneficial prognostic factor for overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and parotid relapse-free survival (PRFS). CONCLUSION: Based on the distribution pattern of PLN metastasis in NPC and the result of dose-finding study, involving the ipsilateral level VIII into low-risk clinical target volume (CTV2) is recommended for NPC with PLN metastasis.
引用
- Lin C, Lu N, Liang JL, et al. Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma. Radiother Oncol. 2023. PMID: 37423477. doi:10.1016/j.radonc.2023.109802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。